• Rhythm Pharmaceuticals presented new clinical data on setmelanotide in adults with acquired hypothalamic obesity at the 2026 European Congress of Endocrinology.
• The data showed meaningful BMI reductions and improved cardiometabolic outcomes in treated adults.
• These findings follow recent pediatric efficacy results shared at the PES Annual Meeting, adding to the evidence base for IMCIVREE across different patient groups.
• The updates arrive shortly after regulatory approvals and commercial launch expansions in the US and Europe.

For investors tracking NasdaqGM:RYTM, these new clinical results add fresh clinical context to a stock that has moved sharply over the longer term, with a very large 3 year gain and a 305.1% return over 5 years. The shares most recently closed at $91.31, with the stock up 60.8% over the past year and up 8.2% over the past 30 days, despite being down 13.0% year to date and down 1.1% over the past week.

With IMCIVREE launch activities progressing in both the US and Europe, the latest adult and pediatric data around BMI and cardiometabolic outcomes could become key talking points in physician and payer discussions. Readers may want to watch how prescription trends, reimbursement decisions and future updates from Rhythm Pharmaceuticals intersect with this expanding clinical dataset around acquired hypothalamic obesity.

Stay updated on the most important news stories for Rhythm Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Rhythm Pharmaceuticals.

The fresh adult data on setmelanotide in acquired hypothalamic obesity extends what you already saw in pediatrics, which matters because IMCIVREE is now approved in both the US and Europe for this rare condition. Showing BMI reductions alongside cardiometabolic improvements helps position the drug as more than a pure weight metric story, which can be important in discussions with endocrinologists and payers. For a company already reporting US$60.11 million of quarterly revenue and still carrying a quarterly net loss of US$55.64 million, evidence that supports broader and sustained use in a defined patient group ties directly to how investors think about future volumes and pricing durability.

How This Fits Into The Rhythm Pharmaceuticals Narrative

• The adult and pediatric datasets support the existing narrative that expansion into new indications and age groups can widen the patient base for IMCIVREE, especially in acquired hypothalamic obesity.
• The safety profile, including events such as skin hyperpigmentation, depression and adrenal insufficiency in specific subgroups, underlines the narrative risk around heavy reliance on a single drug and the need for careful monitoring.
• The growing body of real world and long term clinical data on acquired hypothalamic obesity may not be fully reflected in earlier narrative views that focused more heavily on EMANATE outcomes and pipeline optionality.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Rhythm Pharmaceuticals to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Rhythm still reports sizable losses, including a US$55.64 million net loss in the latest quarter, so higher clinical visibility does not yet translate into profitability.
• ⚠️ Safety and monitoring requirements for IMCIVREE, such as depression, hypersensitivity and adrenal insufficiency in certain patients, could influence physician comfort and payer criteria, particularly as competitors like Novo Nordisk, Eli Lilly and others shape obesity treatment expectations.
• 🎁 Consistent signals of BMI and cardiometabolic improvements in both adults and children with acquired hypothalamic obesity support the case for durable use within approved indications.
• 🎁 Combined with recent US and European approvals and launch progress, the expanding evidence base reinforces Rhythm’s positioning in rare neuroendocrine obesity compared with broader obesity players such as Novo Nordisk and Eli Lilly that are less focused on hypothalamic injury.

What To Watch Going Forward

From here, pay attention to how the new adult data influences prescribing patterns in acquired hypothalamic obesity, including how many patients move from trials or early access into commercial therapy. Reimbursement decisions country by country in Europe, payer coverage in the US and any updates to safety labeling will be key for assessing how large and durable the commercial opportunity can be. Investors may also want to monitor commentary at upcoming conferences and earnings calls on how IMCIVREE uptake compares with earlier expectations and how it supports Rhythm’s effort to narrow quarterly losses over time.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Rhythm Pharmaceuticals, head to the community page for Rhythm Pharmaceuticals to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.